A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT

NCT00791947 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

166

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T-Cell Lymphoma

Interventions

DRUG: CHOEP + G-CSF followed by BEAM

Sponsor

University of Aarhus

Collaborators

[object Object]